In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.88 below Myriad Genetics Inc average.

Within In Vitro & In Vivo Diagnostic Substances industry 10 other companies have achieved higher Quick Ratio than Myriad Genetics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1675 to 1913.

Explain Quick Ratio?
How much Cash & cash equivalents MYGN�s has?
What are MYGN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MYGN Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-34.62 %	-13.83 %	-18.46 %	-4.08 %	34.25 %
Y / Y Cash & cash equivalent Change	54.84 %	35.51 %	46.09 %	45.55 %	-23.54 %
Quick Ratio MRQ	0.88	0.96	1.12	0.98	0.37
MYGN's Total Ranking	# 1913	# 1675	# 903	# 1573	# 1788
Seq. Current Liabilities Change	0.38 %	-2.69 %	-9.59 %	-25.96 %	32.3 %
Seq. Cash & cash equivalent Change	-7.4 %	-16.84 %	2.89 %	95.43 %	-18.95 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 11
Healthcare Sector	# 646
Overall Market	# 1913

Quick Ratio Statistics
High	Average	Low
12.04	2.74	0.37
(Dec 31 2010)		(Jun 30 2025)

Financial Statements
Myriad Genetics Inc 's Current Liabilities	$ 131 Millions	Visit MYGN's Balance sheet
Myriad Genetics Inc 's Cash & cash equivalent	$ 115 Millions	Visit MYGN's Balance sheet
Source of MYGN's Sales		Visit MYGN's Sales by Geography

Cumulative Myriad Genetics Inc 's Quick Ratio

MYGN's Quick Ratio for the trailling 12 Months

MYGN Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-18.93 %	-1.05 %	3.16 %	9.57 %	1.39 %
Y / Y Cash & cash equivalent TTM Growth	45.07 %	26.16 %	14.19 %	-6.42 %	-14.06 %
Quick Ratio TTM	0.99	0.81	0.73	0.62	0.55
Total Ranking TTM	# 3985	# 3130	# 2333	# 2065	# 1825
Seq. Current Liabilities TTM Growth	-11.31 %	-3.3 %	-4.57 %	-0.94 %	8.25 %
Seq. Cash & cash equivalent TTM Growth	8.26 %	7.07 %	11.4 %	12.35 %	-5.85 %

Quick ratio ranking by company, industry and sector >> Back to MYGN Financial Strength Comparisons >> Go to Compare MYGN Quick Ratio to its Competitors

On the trailing twelve months basis MYGN Cash & cash equivalent soared by 54.84 % in Q2 2026 year on year, while Current Liabilities rose to $131 millions, this led to increase in in Myriad Genetics Inc 's Quick Ratio to 0.99, Quick Ratio remained below MYGN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Myriad Genetics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3130 to 3985.

Explain Quick Ratio?
How much Cash & cash equivalents MYGN�s has?
What are MYGN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 893
Within the Market	# 3985

trailing twelve months Quick Ratio Statistics
High	Average	Low
5.17	1.46	0.55
(Sep 30 2013)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Lantheus Holdings Inc	1.77	$ 593.298 Millions	$ 335.677 Millions
Insight Molecular Diagnostics Inc	1.73	$ 17.756 Millions	$ 10.286 Millions
Achieve Life Sciences Inc	1.65	$ 326.645 Millions	$ 197.657 Millions
Immucell Corporation	1.51	$ 8.860 Millions	$ 5.863 Millions
Myriad Genetics Inc	0.88	$ 115.200 Millions	$ 130.700 Millions
Biomerica Inc	0.53	$ 1.308 Millions	$ 2.481 Millions
Volitionrx Limited	0.21	$ 2.800 Millions	$ 13.493 Millions
Neogen Corporation	0.20	$ 185.500 Millions	$ 916.900 Millions

Date modified: 2026-08-13T09:19:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.